$69.5 M

HARP Mkt cap, 11-May-2022
Harpoon Therapeutics Cash, 31-Dec-202021.2 M
Harpoon Therapeutics EV61.8 M
Get notified regarding key financial metrics and revenue changes at Harpoon TherapeuticsLearn more
Banner background

Harpoon Therapeutics Income Statement

Annual

USDFY, 2016FY, 2017

Revenue

708.0k

R&D expense

7.8m13.6m

General and administrative expense

3.4m3.6m

Operating expense total

11.1m17.2m

EBIT

(11.1m)(16.5m)

EBIT margin, %

(2334%)

Interest expense

261.0k285.0k

Net Income

(11.4m)(16.8m)

Harpoon Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

985.0k29.4m89.5m88.7m21.2m

Prepaid Expenses

559.0k224.0k730.0k2.5m3.7m

Current Assets

8.3m29.6m90.2m150.6m129.8m

PP&E

90.0k2.1m3.0m11.4m10.2m

Total Assets

8.4m31.9m102.6m176.6m171.6m

Accounts Payable

281.0k1.2m4.4m2.6m1.6m

Short-term debt

1.2m1.2m

Current Liabilities

3.9m6.9m11.9m22.5m47.9m

Long-term debt

13.7m12.3m

Total Debt

14.9m13.5m

Total Liabilities

3.9m19.0m26.5m82.4m117.8m

Common Stock

1.0k1.0k1.0k3.0k3.0k

Preferred Stock

14.9m39.8m

Additional Paid-in Capital

8.0m8.3m9.1m212.3m221.9m

Retained Earnings

(18.4m)(35.2m)(62.6m)(118.2m)(168.1m)

Total Equity

4.5m12.9m(53.5m)94.2m53.8m

Financial Leverage

1.9 x2.5 x-1.9 x1.9 x3.2 x

Quarterly

USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

27.9m95.9m52.1m56.8m36.2m34.7m22.7m

Prepaid Expenses

1.1m2.1m3.4m1.8m5.6m3.2m2.9m

Current Assets

28.9m140.7m137.3m123.0m128.7m174.8m157.7m

PP&E

2.3m5.5m11.8m11.8m11.0m10.8m10.5m

Total Assets

32.3m166.9m157.0m142.4m162.5m197.1m183.3m

Accounts Payable

1.7m3.4m4.5m3.9m1.5m1.6m1.8m

Short-term debt

1.3m1.3m1.4m

Current Liabilities

7.6m11.9m14.5m16.7m23.8m39.0m45.2m

Long-term debt

14.7m14.4m14.1m13.4m13.1m12.7m

Total Debt

14.7m14.4m14.1m14.7m14.4m14.1m

Total Liabilities

16.5m33.3m34.5m35.2m79.2m125.2m122.6m

Common Stock

1.0k3.0k3.0k3.0k3.0k3.0k3.0k

Preferred Stock

59.8m

Additional Paid-in Capital

8.9m209.7m210.3m211.0m213.5m215.1m217.3m

Retained Earnings

(52.9m)(76.2m)(88.0m)(103.9m)(130.7m)(143.4m)(156.7m)

Total Equity

15.8m133.6m122.5m107.2m83.3m71.9m60.7m

Financial Leverage

2 x1.2 x1.3 x1.3 x2 x2.7 x3 x

Harpoon Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(11.4m)(16.8m)(27.4m)(55.6m)(49.9m)

Depreciation and Amortization

198.0k366.0k644.0k900.0k2.1m

Accounts Payable

570.0k804.0k2.6m(1.8m)(1.2m)

Cash From Operating Activities

(10.8m)1.7m(27.1m)(2.9m)(8.6m)

Purchases of PP&E

(553.0k)(2.3m)(663.0k)(3.5m)(683.0k)

Cash From Investing Activities

(553.0k)4.5m(663.0k)(69.3m)(63.6m)

Cash From Financing Activities

10.0m22.2m88.3m71.4m4.7m

Net Change in Cash

(1.4m)28.4m60.5m(757.0k)(67.6m)

Quarterly

USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(11.9m)(17.6m)(13.6m)(25.4m)(41.3m)(12.6m)(25.2m)(38.6m)

Depreciation and Amortization

244.0k447.0k297.0k596.0k400.0k503.0k1.0m1.5m

Accounts Payable

(12.0k)(10.0k)(771.0k)(876.0k)(697.0k)(1.1m)(1.0m)(815.0k)

Cash From Operating Activities

(10.9m)(20.7m)(12.4m)(25.4m)(36.6m)(17.5m)20.0m6.6m

Purchases of PP&E

(2.3m)(506.0k)(72.0k)(1.4m)(3.1m)(5.0k)(155.0k)(625.0k)

Cash From Investing Activities

4.5m(506.0k)(51.6m)(82.9m)(67.0m)(35.3m)(74.4m)(74.1m)

Cash From Financing Activities

22.2m20.1m70.5m70.8m70.9m265.0k366.0k1.4m

Net Change in Cash

15.8m(1.1m)6.4m(37.4m)(32.7m)(52.6m)(54.0m)(66.1m)

Harpoon Therapeutics Ratios

USDFY, 2016

Financial Leverage

1.9 x

Harpoon Therapeutics Employee Rating

4.39 votes
Culture & Values
5
Work/Life Balance
4.5
Senior Management
5
Salary & Benefits
4
Career Opportunities
4.8
Source